Abbott completes acquisition acquisition of held eye treatment company Visiogen privately Abbott has completed its acquisition of privately held eye treatment organization Visiogen, expanding the company’s vision care business with a next-generation accommodating intraocular zoom lens technology to handle presbyopia for cataract patients. It is designed to mimic the eye’s natural ability to change focus , delivering improved eyesight at all distances, eliminating the need for glasses or contact lenses potentially, reducing glare and nighttime halos, and improving contrast sensitivity caverta online .
ABT-335 is certainly Abbott’s next-generation fenofibrate presently in late-stage medical trials. Based on the significant progress manufactured in the ABT-335 and CRESTOR fixed-dose mixture development program, the firms have jointly decided to progress with this fixed-dose combination therapy. The scholarly studies are proceeding on schedule. Related StoriesBlocking calcium-signaling pathway could inhibit Ebola virus and other sources of deadly infectionsFour microRNAs may actually play critical functions in controlling cholesterol, triglyceride metabolismNew vaccine is apparently more effective in reducing 'bad' LDL cholesterol This decision highlights the opportunity for broader treatment in many higher at-risk populations, said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.